Less severe disease in patients with early systemic sclerosis?

References

• Denton CP. Systemic sclerosis: from pathogenesis to targeted therapy. Clin Exp Rheumatol. 2015;33(4 Suppl 92):S3–S7. [PMC][https://doi.org/26457375]
   PubMed Web of Science ®Google Scholar
• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–99.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Bellando-Randone S, Lepri G, Bruni C, Guiducci S. Very early versus early disease: the evolving definition of the 'many faces' of systemic sclerosis. Ann Rheum Dis. 2013;72(3):319–21.
   PubMed Web of Science ®Google Scholar
• Bellando-Randone S, Guiducci S, Matucci-Cerinic M. Very early diagnosis of systemic sclerosis. Pol Arch Med Wewn. 2012;122(Suppl 1):18–23.
   PubMed Web of Science ®Google Scholar
• van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–47.
   PubMed Web of Science ®Google Scholar
• Johnson SR. New ACR EULAR guidelines for systemic sclerosis classification. Curr Rheumatol Rep. 2015;17(5):32
   PubMed Web of Science ®Google Scholar
• Jordan S, Maurer B, Toniolo M, Michel B, Distler O. Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice. Rheumatology (Oxford). 2015;54(8):1454–8.
   PubMed Web of Science ®Google Scholar
• Wigley FM. When is scleroderma really scleroderma? J Rheumatol. 2001;28(7):1471–3.
   PubMed Web of Science ®Google Scholar
• Pamuk ON, Balcı MA, Onat AM, Zengin O, Cakır N, Kısacık B. Performance of the new American College of Rheumatology classification criteria in Turkish systemic sclerosis patients: a multicenter study. Clin Rheumatol. 2016;35(2):357–61.
   PubMed Web of Science ®Google Scholar
• Medsger TA. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am. 2003;29(2):255–73.
   PubMed Web of Science ®Google Scholar
• Harel D, Hudson M, Iliescu A, Baron M, Steele R, Pope J, et al. Summed and weighted summary scores for the Medsger Disease Severity Scale compared with the Physician's Global Assessment of disease severity in systemic sclerosis. J Rheumatol. 2016;43(8):1510–8.,
   PubMed Web of Science ®Google Scholar
• Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis. 2001;60(6):592–8.
   PubMed Web of Science ®Google Scholar
• Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P, et al. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76(1):270–6.
   PubMed Web of Science ®Google Scholar
• Medsger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S42–S6.
   PubMed Web of Science ®Google Scholar
• Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980;23:581–90.
   PubMed Web of Science ®Google Scholar
• LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.
   PubMed Web of Science ®Google Scholar
• Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol. 1995;22:1281–5.
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137–45.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum. 1997;40(11):1984–91.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42–50.
   PubMed Web of Science ®Google Scholar
• Medsger TA, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999;26:2159–67.
   PubMed Web of Science ®Google Scholar
• Distler O, Allanore Y, Denton CP, Matucci-Cerinic M, Pope JE, Hinzmann B, et al. Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2018;57(5):813–7.
   PubMed Web of Science ®Google Scholar
• Nevskaya T, Baron M, Pope JE, Group CSR. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort. Rheumatology (Oxford). 2017;56(7):1111–22.
   PubMed Web of Science ®Google Scholar
• Foocharoen C, Distler O, Becker M, Müller-Ladner U, von Mühlen C, Leuchten N, et al. Clinical correlations of hypocomplementaemia in systemic sclerosis: an analysis of the EULAR Scleroderma Trial and Research group (EUSTAR) database. Scand J Rheumatol. 2012;41(3):243–6.
   PubMed Web of Science ®Google Scholar
• Fan X, Pope J, Baron M, Group CSR. What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). Rheumatol Int. 2010;30(9):1205–10.
   PubMed Web of Science ®Google Scholar
• Steen VD, Medsger TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000;43(11):2437–44.
   PubMed Web of Science ®Google Scholar
• Jaeger VK, Wirz EG, Allanore Y, Rossbach P, Riemekasten G, Hachulla E, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016;11(10):e0163894.
   PubMed Web of Science ®Google Scholar
• Walker JG, Steele RJ, Schnitzer M, Taillefer S, Baron M, Hudson M, et al. The association between disease activity and duration in systemic sclerosis. J Rheumatol. 2010; 37(11):2299–306.
   PubMed Web of Science ®Google Scholar
• Lilienfeld AM. Practical limitations of epidemiologic methods. Environ Health Perspect. 1983;52:3–8.
   PubMed Web of Science ®Google Scholar